Fasting is not starvation or a fad, it is a discipline: Luke Coutinho – The Indian Express
stemadminBenefits Of Stem CellsNo comments

Written by Jayashree Narayanan | Pune | Updated: July 9, 2020 6:38:55 pm Lifestyle coach Luke Coutinho on dry fasting and why it matters for your body. (Source: PR Handout) Dry fasting for good health has raised eyebrows for its complete abstinence from food and water for an extended period, but the trend has been presented as a superior form of fasting and cleansing by Luke Coutinho in his book The Dry Fasting Miracle: From Deprive to Thrive, published by Penguin Random House India. Coutinho, a holistic lifestyle coach-integrative medicine, who has co-authored the book with Sheikh Abdul Aziz Nuaimi aka Green Sheikh, from UAEs Ajman royal family, advocates dry fasting and intermittent fasting for healthy living.

Read more
FDA Approves Talaris Therapeutics’ IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma -…
stemadminBenefits Of Stem CellsNo comments

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com

Read more
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration – BioSpace
stemadminBenefits Of Stem CellsNo comments

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the companys principal contract development and manufacturing partners, today announced that they have extended their collaboration initiated in April 2018 for a period of five years through June 2025. With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies in the upcoming years, including OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott Aldrich syndrome (WAS), as well as for additional pipeline programs including OTL-203 for mucopolysaccharidosis type I (MPS-I). MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

Read more
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+…
stemadminBenefits Of Stem CellsNo comments

BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center.

Read more
Hematopoietic Stem Cells Transplantation Market to Eyewitness Massive Growth by 2028: Leading Key Players Kite Pharma, Thermo Fisher Scientific,…
stemadminBenefits Of Stem CellsNo comments

JCMR recently Announced Hematopoietic Stem Cells Transplantationstudy with 200+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Global Hematopoietic Stem Cells Transplantation Market. Global Hematopoietic Stem Cells Transplantation Marketallows you to get different methods for maximizing your profit

Read more

Theme: Illdy.